NCT02651909View on ClinicalTrials.gov

Utilization of TEG to Monitor Rivaroxaban Activity

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

July 7, 2018

Study Completion Date

November 4, 2019

Conditions
AnemiaVenous Thrombosis
Interventions
OTHER

blood sampling

blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay

Trial Locations (1)

15213

University of Pittsburgh Medical Center, PUH, 200 Lothrop Street, Pittsburgh

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Matthew Neal MD

OTHER

NCT02651909 - Utilization of TEG to Monitor Rivaroxaban Activity | Biotech Hunter | Biotech Hunter